Day: March 28, 2022

Press Release March 28, 2022 Signify completes share repurchase program to cover performance share plans Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has completed its previously announced share repurchase program. The company repurchased a total of 850,000 shares for a total consideration of EUR 35.5 million from February 24 to March 25, 2022. These repurchases were made as part of the company’s repurchase program, which was announced on February 24, 2022. Signify will use the shares to cover obligations arising from its long-term incentive performance share plans and other employee share plans. In the period March 21 to March 25, 2022, the company repurchased 195,704 shares at an average price of EUR 43.15 per share and an aggregate amount of EUR 8.4m. Details on the share...

PHILADELPHIA, March 28, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in the following upcoming virtual investor conferences: Guggenheim 3rd Annual Genomic Medicines & Rare Disease Day Format: Fireside ChatDate: Thursday, March 31, 2022Time: 9:00 a.m. ET 21st Annual Needham Virtual Healthcare ConferenceFormat: PresentationDate: Wednesday, April 13, 2022Time: 2:15 p.m. ET Chardan Genetic Medicines and Cell Therapy Manufacturing Summit Format: PresentationDate: Tuesday, April 26, 2022Time: 11:30 a.m. ET A live webcast of these events will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com....

NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) announced today that Prospect’s preferred stock offerings (collectively, the “Preferred Stock”) have reached approximately $600 million in aggregate liquidation preference issuances since the initial closing in the quarter ending December 31, 2020. “Prospect’s preferred stock offers investors recurring cash income with a stable stated value, ongoing liquidity, management alignment, leverage caps, and over $4 billion of junior common equity credit support,” said Grier Eliasek, President of Prospect. “Each of the institutional, registered investment advisors, wirehouse, independent private wealth, and international investor channels have invested in Prospect’s preferred stock.” Preferred...

Figure 1 Industry Position of Medallion Technology PlatformsVANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN – “Medallion” or the “Company”), is pleased to announce signing of an exclusivity agreement (the “Exclusivity Agreement”) with a private North American research company (the “Research Partner”) to provide a three-month period to undertake additional due diligence on proprietary rare earth element metallization and rare earth magnet recycling technologies. If the technical due diligence is successful, Medallion will seek to negotiate investment terms to acquire or partner on all or part of the underlying technologies. The Research Partner is the exclusive owner and developer of an innovative rare earth element (“REE”) metallization technology....

TORONTO, March 28, 2022 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) provides notice that the Annual General Meeting of shareholders of the Company will take place on May 5, 2022 at 9:00 am (EDT) online via audio webcast through the Company’s website (www.first-quantum.com) or directly at https://meetnow.global/MM7MLTC.  ANNUAL DISCLOSURE DOCUMENTS The Company’s 2021 Annual Report (which includes the Company’s audited annual financial statements for the year ended December 31, 2021 and the corresponding management’s discussion and analysis), Annual Information Form and 2022 Notice & Access Document, Notice of Meeting, Management Information Circular, Proxy Form, Financial Statements Request Form and Voting Instruction Form are now available online at https://www.first-quantum.com/English/investors/investor-briefcase/default.aspx. For...

TORONTO, March 28, 2022 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or “the Company”) (TSX: CG) (NYSE: CGAU) issued the following statement today: Centerra Gold Inc. notes that the Cabinet of Ministers of the Kyrgyz Republic has approved a decision by the Kyrgyz Government to conclude an agreement with Centerra related to Centerra’s Kumtor Mine, as reported by Kyrgyz news media. Negotiations with representatives of the Kyrgyz Government and Kyrgyzaltyn JSC continue with a view to finalizing a transaction that Centerra expects will include the principal terms outlined in the Company’s press release dated January 3, 2022. As previously disclosed, Centerra expects that the framework for any transaction will include exchanging Centerra’s interest in the Kumtor Mine for, among other things, Kyrgyzaltyn JSC’s Centerra common shares,...

Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea Acquisition accelerates Axsome’s transformation into a global commercial entity ahead of potential near-term launches of AXS-05 in major depressive disorder (MDD) and AXS-07 in migraine Highly synergistic with Axsome’s existing neuroscience portfolio and Digital Centric Commercialization™ (DCC) platform Anticipated long-lived exclusivity for Sunosi with potential for significant additional indications Immediately revenue generating, and expected to be breakeven to operating plan in 2023, and substantially accretive thereafter Company to host conference call today at 8:00 AM ET NEW YORK, March 28,...